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Abstract No effective treatment for delayed radiation-
induced neurotoxicity has been established. Its natural
course is highly variable, but spontaneous recovery has
been well documented. Here we report our experience with
therapeutic anticoagulation in patients with cerebral lesions
(n = 3), cranial nerve lesions (n = 1) or myelopathy
(n = 4) attributed to irradiation. Two of three patients with
cerebral lesions and the patient with cranial nerve lesions
showed a minor improvement of clinical symptoms. In
contrast, none of the patients with radiation myelopathy
improved. No patient suffered hemorrhage or other adverse
effects of anticoagulation. Overall, anticoagulation therapy
demonstrates only modest activity for delayed radiation-
induced neurotoxicity in this small case series.
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Abbreviations
CHOP Cyclophosphamide, doxorubicin, oncovin
(vincristine), prednisolone
FEC 5-Fluorouracil, epirubicin, cyclophosphamide
FLAIR Fluid attenuated inversion recovery
LMWH Low molecular weight heparin
MRI Magnetic resonance imaging
MTX Methotrexate
NHL Non-Hodgkin lymphoma
PCNSL Primary CNS lymphoma
PCV Procabazine, CCNU (lomustine), vincristine
RT Radiotherapy
T1w T1 weighted
UH Unfractionated heparin
VAD Vincristine, adriablastin, dexamethasone
WBRT Whole brain radiotherapy
Introduction
Potentially irreversible treatment-induced damage to the
nervous system has become a relevant management prob-
lem as more cancer patients experience prolonged survival.
Long-term radiation-induced neurotoxicity includes cere-
bral radionecrosis, diffuse cerebral white matter changes,
radiation myelopathy, and plexus lesions [1–3]. There may
be spontaneous recovery, but most clinical symptoms
associated with radiation-induced neurotoxicity are slowly
progressive. Treatment with steroids is often insufficiently
effective and associated with significant side effects when
administered for months. Since a vascular pathogenesis has
been proposed to mediate some of these symptoms, anti-
coagulation using heparin and warfarin has been explored
for possible efficacy [4, 5]. The largest series [5] reported
some recovery of function in 5 of 8 patients with cerebral
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radionecrosis and all of 3 patients with myelopathy or
plexopathy (1 myelopathy, 2 plexopathies). A further
treatment option is hyperbaric oxygen therapy, based on
the assumption that oxygen therapy induces neovasculari-
zation [6–8]. Finally, some patients with radiation-induced
neurotoxicity may benefit from oral treatment with bo-
swellic acid-containing medicines such as H15 [9]. Here
we report our experience with anticoagulation using hep-
arin or warfarin or both sequentially as an experimental
treatment for delayed radiation-induced neurotoxicity.
Patients and methods
We searched the charts of the Department of Neurology
from 1998 to 2007 for patients who received heparin or
warfarin or both for the treatment of suspected radiation-
induced injury to the nervous system. The diagnosis of
radiation injury was based on clinical symptoms and signs
that could not be attributed to progressive or recurrent
tumor as defined by neuroimaging or to any other neuro-
logical disease. Moreover, a history of irradiation of the
nervous system region affected was required. Eight patients
were identified. Clinical histories, neuroimaging studies
and the evolution of symptoms were reviewed.
Results
In 1998, it became practice at our institution to offer
anticoagulation to patients with a tentative diagnosis of
radiation-induced injury to the nervous system who had not
responded to steroids and who had no contraindications for
this treatment. Patient characteristics are summarized in the
Table 1. There were 3 patients with cerebral lesions, one
patient with cranial nerve lesions, and 4 patients with
radiation-induced myelopathy. None of the patients had a
biopsy of the lesion before anticoagulation was started, but
the neuroradiological features were not suggestive of
recurrent tumor in any patient (Fig. 1a). Neuroimaging
findings were consistent with radiation injury (Fig. 2).
Spectroscopy performed in one patient supported the
diagnosis of radiation-induced leukencephalopathy
(Fig. 1b). An unusual treatment predicted to induce radia-
tion injury to the nervous system was only given to patient
2 who received two courses of WBRT for PCNSL. Six
patients had also received chemotherapy before, during or
after radiotherapy, which may have contributed to radiation
injury of the nervous system. This is particularly true for
patient 6 who had received multiple courses of intrathecal
chemotherapy, too.
Patients 3, 4, 5, and 6 had had a prior course of steroids
and had not responded. No patient was on steroids when
anticoagulation was started. No patient was newly started
on steroids when anticoagulation was instituted, excluding
confounding effects of steroid comedication.
Two out of three patients with cerebral lesions (patients 2
and 3) and the patient with cranial nerve lesions (patient 4)
showed a minor improvement of their clinical symptoms.
These patients were switched from heparin to warfarin after a
few days because the minor clinical response were seen
early. Patient 1 refused to continue warfarin beyond day 2. In
contrast, none of the patients with radiation myelopathy
improved clinically, although patient 7 showed a distinct
regression on MR imaging (Fig. 3). Although this might be
attributed to the anticoagulation therapy, it possibly occurred
as a result of subsequent hyperbaric oxygen therapy or
spontaneous recovery. Since the patient cohort reported
earlier [5] included only one patient suffering radiation-
induced myelopathy, the evaluation on the effects of anti-
coagulation on radionecrosis of the myelon is only
preliminary.
Our patients 2 and 3 improved with regard to level of
consciousness and hemiparesis within 3 days of the insti-
tution of anticoagulation, raising the possibility that
anticoagulation was the cause for improvement. Partial
remission of cranial nerve palsies took days in patient 4,
rendering a causal relationship to anticoagulation more
doubtful. The neurological deficits in the 4 patients with
radiation myelopathy remained stable throughout the
therapeutic trial of anticoagulation. No patient suffered
hemorrhage or other adverse effects of anticoagulation
therapy.
Discussion
The increasing use of more efficacious multimodality
treatments for various types of cancer results in significant
survival benefits for many patients, but has also raised
awareness for therapy-related injury to the nervous system.
Such lesions may often be multifactorial in origin and not
only caused by irradiation, but also to chemotherapy, pre-
existing comorbidities, notably diabetes and cerebrovas-
cular disease, as well as the underlying cancer itself.
Although it is often difficult to distinguish radiation injury
from recurrent tumor, such patients rarely undergo a biopsy
for a histological verification of radiation injury to the
nervous system.
Steroids, anticoagulation [5], hyperbaric oxygen [6–8]
and boswellic acids [9] have been proposed to alleviate
neurological deficits associated with delayed radiation-
induced neurotoxicity. Given the relative rarity of this
condition and the heterogeneity of patient characteristics, it
is unlikely that prospective randomized trials may ever
been performed to standardize management. Moreover,
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there may be distinct differences in the pathogenesis of
various syndromes of radiation injury. Accordingly, spe-
cific syndromes may respond differentially to treatments
such as steroids, anticoagulation or hyperbaric oxygen.
Steroids are considered to be effective mainly for acute and
subacute radiation-induced injury to the nervous system.
No further studies on the possible beneficial role of
anticoagulation have been published since 1994 [5]. The
rationale of anticoagulation is based on histological
observations of endothelial damage and lesions induced by
irradiation [10]. The case series reported here is only the
second in the literature to assess this treatment. Patients
who responded clinically to i.v. heparin did so early and
were then switched to warfarin. The only patient who
experienced no benefit from warfarin discontinued warfarin
anticoagulation after 2 days. Thus we feel that our obser-
vations justify a short trial of up to a week of
anticoagulation with i.v. heparin in patients with pre-
sumptive radiation-induced cerebral lesions whereas the
lack of any change in the symptoms and signs of all 4
Fig. 1 (a) Sixty three year old
woman presenting with
disturbance of memory after
WBRT with 36 Gy (patient 1).
Upper row (A, axial FLAIR and
post contrast T1w images)
shows several lesions (black
arrows) with homogenous
contrast enhancement and
pronounced perifocal edema
representing an intracerebral
lymphoma. Lower row (B, axial
FLAIR and post contrast T1w
images) represents a follow up
examination 10 months after
radiation therapy showing a
pathologic signal in FLAIR
images (arrow heads) in the
periventricular white matter
with no evidence of tumor
recurrence in post contrast T1w
images. (b) Patient 1: single
voxel spectroscopy shows an
elevated lactate peak in the
periventricular white matter
(white arrow), consistent with
active inflammation, and
strongly suggestive of radiation
injury. MRI ruled out tumor
recurrence
Fig. 2 Thirty nine year old man
after irradiation of a
glioblastoma in the right parietal
lobe (patient 3). Axial T1w,
contrast-enhanced T1w, and
FLAIR images are presented
from left to right. A star-shaped,
hemorrhagic, contrast-
enhancing lesion (arrow) and a
large edema (asterisk),
consistent with a radiation
injury, can be appreciated in the
right parietal lobe
360 J Neurooncol (2008) 90:357–362
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patients with radiation-related myelopathy is not encour-
aging. Moreover, all reports on the apparent beneficial
effects of therapeutic interventions for radiation-associated
neurotoxicity must be considered with caution in view of
the variable course of such lesions which includes spon-
taneous recovery. For instance, it is impossible to say
whether the improvement seen in patient 7 (Fig. 3) was
related to heparin or hyperbaric oxygen or reflected the
natural course of the lesion.
More importantly, there is an increasing awareness of
pseudoprogression of tumors within the CNS as an early
misleading MRI feature after focal radiotherapy. This may
lead to the erroneous assumption of treatment failure and
trigger false therapeutic decisions [11, 12]. In summary, the
present case series demonstrates that anticoagulation therapy
is safe but has probably only modest activity in patients with
delayed radiation-induced neurotoxicity. Prospective stud-
ies using stringent diagnostic criteria for therapy-induced
Fig. 3 Fifty three year old man
(patient 7) with multiple
myeloma after spinal irradiation
of Th 5–7 with 32 Gy. Sagittal,
contrast-enhanced T1w (upper
row), sagittal T2w (middle
row), and axial T2w images
(lower row) are shown. The first
MRI showed a pronounced
edema of the myelon at the level
Th 5–9 and a significant contrast
uptake (A, white arrows). Three
months later, MRI showed
regression with residual edema
and reduced contrast uptake of
the myelon at the level Th 5–6
(B, white arrows); 10 days of
i.v. heparin therapy and 6 weeks
of fraxiparine therapy as well as
40 administrations of hyperbaric
oxygen had preceded the MRI.
Follow-up 7 months after initial
examination showed further
improvement with only minimal
residual findings (C, white
arrows). Another 40
applications of hyperbaric
oxygen had been administered
J Neurooncol (2008) 90:357–362 361
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injury to the nervous system are required to explore in more
depth the therapeutic potential of both anticoagulants and
hyperbaric oxygen therapy.
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